The Cancer Genome Atlas (TCGA) Research Network conducted a comprehensive genomic analysis of 206 glioblastomas (GBMs), the most common type of adult brain cancer, and 91 of these tumors were sequenced for nucleotide sequence aberrations. The study identified key genes and pathways involved in GBM development, including ERBB2, NF1, and TP53, and revealed frequent mutations in the PI3K regulatory subunit gene PIK3R1. The analysis also uncovered a link between MGMT promoter methylation and a hypermutator phenotype in treated GBMs, which has potential clinical implications. Integration of mutation, DNA methylation, and clinical data showed that MGMT methylation is associated with a shift in mutation spectrum in treated GBMs, suggesting a role in treatment resistance. The study also identified core pathways involved in GBM pathogenesis, including receptor tyrosine kinase (RTK) signaling and the p53/RB tumor suppressor pathways. The findings demonstrate the feasibility and power of TCGA in rapidly expanding knowledge of the molecular basis of cancer. The study highlights the importance of comprehensive genomic characterization in understanding cancer biology and developing targeted therapies. The results provide a framework for future research and therapeutic strategies in GBM.The Cancer Genome Atlas (TCGA) Research Network conducted a comprehensive genomic analysis of 206 glioblastomas (GBMs), the most common type of adult brain cancer, and 91 of these tumors were sequenced for nucleotide sequence aberrations. The study identified key genes and pathways involved in GBM development, including ERBB2, NF1, and TP53, and revealed frequent mutations in the PI3K regulatory subunit gene PIK3R1. The analysis also uncovered a link between MGMT promoter methylation and a hypermutator phenotype in treated GBMs, which has potential clinical implications. Integration of mutation, DNA methylation, and clinical data showed that MGMT methylation is associated with a shift in mutation spectrum in treated GBMs, suggesting a role in treatment resistance. The study also identified core pathways involved in GBM pathogenesis, including receptor tyrosine kinase (RTK) signaling and the p53/RB tumor suppressor pathways. The findings demonstrate the feasibility and power of TCGA in rapidly expanding knowledge of the molecular basis of cancer. The study highlights the importance of comprehensive genomic characterization in understanding cancer biology and developing targeted therapies. The results provide a framework for future research and therapeutic strategies in GBM.